| Literature DB >> 34213886 |
Soumen Chakraborty1,2, Rajendra Uprety3, Amal E Daibani1,2, Valerie L Rouzic3, Amanda Hunkele3, Kevin Appourchaux1, Shainnel O Eans4, Nitin Nuthikattu1, Rahul Jilakara1, Lisa Thammavong1, Gavril W Pasternak3, Ying-Xian Pan3,5, Jay P McLaughlin4, Tao Che1,2,6, Susruta Majumdar1,2.
Abstract
Dry leaves of kratom (mitragyna speciosa) are anecdotally consumed as pain relievers and antidotes against opioid withdrawal and alcohol use disorders. There are at least 54 alkaloids in kratom; however, investigations to date have focused around mitragynine, 7-hydroxy mitragynine (7OH), and mitragynine pseudoindoxyl (MP). Herein, we probe a few minor indole and oxindole based alkaloids, reporting the receptor affinity, G-protein activity, and βarrestin-2 signaling of corynantheidine, corynoxine, corynoxine B, mitraciliatine, and isopaynantheine at mouse and human opioid receptors. We identify corynantheidine as a mu opioid receptor (MOR) partial agonist, whereas its oxindole derivative corynoxine was an MOR full agonist. Similarly, another alkaloid mitraciliatine was found to be an MOR partial agonist, while isopaynantheine was a KOR agonist which showed reduced βarrestin-2 recruitment. Corynantheidine, corynoxine, and mitraciliatine showed MOR dependent antinociception in mice, but mitraciliatine and corynoxine displayed attenuated respiratory depression and hyperlocomotion compared to the prototypic MOR agonist morphine in vivo when administered supraspinally. Isopaynantheine on the other hand was identified as the first kratom derived KOR agonist in vivo. While these minor alkaloids are unlikely to play the majority role in the biological actions of kratom, they represent excellent starting points for further diversification as well as distinct efficacy and signaling profiles with which to probe opioid actions in vivo.Entities:
Keywords: Respiration; corynoxine; kratom; mitraciliatine; oxindoles; partial agonism
Mesh:
Substances:
Year: 2021 PMID: 34213886 PMCID: PMC8328003 DOI: 10.1021/acschemneuro.1c00149
Source DB: PubMed Journal: ACS Chem Neurosci ISSN: 1948-7193 Impact factor: 5.780